James Sapirstein - Net Worth and Insider Trading

James Sapirstein Net Worth

The estimated net worth of James Sapirstein is at least $24,964 dollars as of 2024-11-05. James Sapirstein is the Chairman and CEO of Entero Therapeutics Inc and owns about 35,816 shares of Entero Therapeutics Inc (ENTO) stock worth over $24,949. James Sapirstein is also the CEO of Hepion Pharmaceuticals Inc and owns about 23 shares of Hepion Pharmaceuticals Inc (HEPA) stock worth over $15. Details can be seen in James Sapirstein's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that James Sapirstein has not made any transactions after 2024-07-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of James Sapirstein

James Sapirstein Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James Sapirstein owns 11 companies in total, including Entero Therapeutics Inc (ENTO) , Renovaro Inc (RENB) , and Marizyme Inc (MRZM) among others .

Click here to see the complete history of James Sapirstein’s form 4 insider trades.

Insider Ownership Summary of James Sapirstein

Ticker	Comapny	Transaction Date	Type of Owner
ENTO	Entero Therapeutics Inc	2024-07-02	director & President and CEO
RENB	Renovaro Inc	2018-03-06	director
MRZM	Marizyme Inc	2018-12-06	director & Interim Chief Executive Office & other: Executive Chairman
		2016-02-18	director & Chief Executive Officer
		2014-09-03	director
		2015-07-06	director
		2014-01-09	CEO & Therapeutics Division
		2022-02-23	director
		2020-12-15	director
		2023-01-05	director
		2020-12-15	director

James Sapirstein Latest Holdings Summary

James Sapirstein currently owns a total of 2 stocks. Among these stocks, James Sapirstein owns 35,816 shares of Entero Therapeutics Inc (ENTO) as of July 2, 2024, with a value of $24,949 and a weighting of 99.94%. James Sapirstein also owns 23 shares of Hepion Pharmaceuticals Inc (HEPA) as of February 18, 2016, with a value of $15 and a weighting of 0.06%.

Latest Holdings of James Sapirstein

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ENTO	Entero Therapeutics Inc	2024-07-02	35,816	0.70	24,949
HEPA	Hepion Pharmaceuticals Inc	2016-02-18	23	0.65	15

Holding Weightings of James Sapirstein

James Sapirstein Form 4 Trading Tracker

According to the SEC Form 4 filings, James Sapirstein has made a total of 6 transactions in Entero Therapeutics Inc (ENTO) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Entero Therapeutics Inc is the sale of 1,289 shares on July 2, 2024, which brought James Sapirstein around $1,379.

According to the SEC Form 4 filings, James Sapirstein has made a total of 0 transactions in Hepion Pharmaceuticals Inc (HEPA) over the past 5 years. The most-recent trade in Hepion Pharmaceuticals Inc is the acquisition of 18 shares on February 18, 2016, which cost James Sapirstein around $10,000.

Insider Trading History of James Sapirstein

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James Sapirstein Trading Performance

GuruFocus tracks the stock performance after each of James Sapirstein's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James Sapirstein is -42.85%. GuruFocus also compares James Sapirstein's trading performance to market benchmark return within the same time period. The performance of stocks bought by James Sapirstein within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James Sapirstein's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James Sapirstein

Average Return

Average return per transaction

Outperforming Transactions

2 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-8.89
Relative Return to S&P 500(%)	-10.55

James Sapirstein Ownership Network

Ownership Network List of James Sapirstein

No Data

Ownership Network Relation of James Sapirstein

James Sapirstein Owned Company Details

What does Entero Therapeutics Inc do?

Who are the key executives at Entero Therapeutics Inc?

James Sapirstein is the director & President and CEO of Entero Therapeutics Inc. Other key executives at Entero Therapeutics Inc include Chief Financial Officer Sarah Romano , CHIEF FINANCIAL OFFICER Daniel H Schneiderman , and CHIEF MEDICAL OFFICER James Pennington .

Entero Therapeutics Inc (ENTO) Insider Trades Summary

Over the past 18 months, James Sapirstein made 5 insider transaction in Entero Therapeutics Inc (ENTO) with a net sale of 6,280. Other recent insider transactions involving Entero Therapeutics Inc (ENTO) include a net sale of 4,066 shares made by Sarah Romano , a net sale of 6,063 shares made by Charles J Casamento ,

In summary, during the past 3 months, insiders sold 476 shares of Entero Therapeutics Inc (ENTO) in total and bought 0 shares, with a net sale of 476 shares. During the past 18 months, 6,431 shares of Entero Therapeutics Inc (ENTO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,431 shares.

Entero Therapeutics Inc (ENTO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Entero Therapeutics Inc Insider Transactions

No Available Data

What does Renovaro Inc do?

Who are the key executives at Renovaro Inc?

James Sapirstein is the director of Renovaro Inc. Other key executives at Renovaro Inc include 10 percent owner Anderson Wittekind William , 10 percent owner Ole Abildgaard , and Executive Vice President Francois Binette .

Renovaro Inc (RENB) Insider Trades Summary

Over the past 18 months, James Sapirstein made no insider transaction in Renovaro Inc (RENB). Other recent insider transactions involving Renovaro Inc (RENB) include a net sale of 473,180 shares made by Anderson Wittekind William ,

In summary, during the past 3 months, insiders sold 0 shares of Renovaro Inc (RENB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 473,180 shares of Renovaro Inc (RENB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 473,180 shares.

Renovaro Inc (RENB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Renovaro Inc Insider Transactions

No Available Data

What does Marizyme Inc do?

Who are the key executives at Marizyme Inc?

James Sapirstein is the director & Interim Chief Executive Office & other: Executive Chairman of Marizyme Inc. Other key executives at Marizyme Inc include 10 percent owner Braeden Lichti , Vice President of Finance Harrison Ross , and Chief Financial Officer Georgiy Kovalyov .

Marizyme Inc (MRZM) Insider Trades Summary

Over the past 18 months, James Sapirstein made no insider transaction in Marizyme Inc (MRZM). Other recent insider transactions involving Marizyme Inc (MRZM) include a net sale of 308,327 shares made by Braeden Lichti ,

In summary, during the past 3 months, insiders sold 0 shares of Marizyme Inc (MRZM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 308,327 shares of Marizyme Inc (MRZM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 308,327 shares.

Marizyme Inc (MRZM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Marizyme Inc Insider Transactions

No Available Data

What does Hepion Pharmaceuticals Inc do?

Who are the key executives at Hepion Pharmaceuticals Inc?

James Sapirstein is the director & Chief Executive Officer of Hepion Pharmaceuticals Inc. Other key executives at Hepion Pharmaceuticals Inc include Chief Scientific Officer Robert T Foster , Chief Financial Officer John T Cavan , and director & CEO and President Gary S Jacob .

Hepion Pharmaceuticals Inc (HEPA) Insider Trades Summary

Over the past 18 months, James Sapirstein made no insider transaction in Hepion Pharmaceuticals Inc (HEPA). Other recent insider transactions involving Hepion Pharmaceuticals Inc (HEPA) include a net purchase of 8,000 shares made by Peter Wijngaard , and a net purchase of 3,200 shares made by Robert T Foster .

In summary, during the past 3 months, insiders sold 0 shares of Hepion Pharmaceuticals Inc (HEPA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Hepion Pharmaceuticals Inc (HEPA) were sold and 11,200 shares were bought by its insiders, resulting in a net purchase of 11,200 shares.

Hepion Pharmaceuticals Inc (HEPA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Hepion Pharmaceuticals Inc Insider Transactions

No Available Data

What does RespireRx Pharmaceuticals Inc do?

Who are the key executives at RespireRx Pharmaceuticals Inc?

James Sapirstein is the director of RespireRx Pharmaceuticals Inc. Other key executives at RespireRx Pharmaceuticals Inc include SVP of Pre-Clinical Prod. Dev. David Dickason , director & CEO and President Timothy L. Jones , and director & President & CEO Manuso James S J .

RespireRx Pharmaceuticals Inc (RSPI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of RespireRx Pharmaceuticals Inc (RSPI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of RespireRx Pharmaceuticals Inc (RSPI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

RespireRx Pharmaceuticals Inc (RSPI)'s detailed insider trading history can be found in Insider Trading Tracker table.

RespireRx Pharmaceuticals Inc Insider Transactions

No Available Data

What does Upstryve Inc do?

Who are the key executives at Upstryve Inc?

James Sapirstein is the director of Upstryve Inc. Other key executives at Upstryve Inc include director & 10 percent owner & Chief Operating Officer Noah Isidore Davis , director & Chief Executive Officer Evan Levine , and director & 10 percent owner & Chief Financial Officer Steven M Plumb .

Upstryve Inc (PBYA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Upstryve Inc (PBYA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Upstryve Inc (PBYA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Upstryve Inc (PBYA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Upstryve Inc Insider Transactions

No Available Data

What does Adynxx Inc do?

Who are the key executives at Adynxx Inc?

James Sapirstein is the CEO & Therapeutics Division of Adynxx Inc. Other key executives at Adynxx Inc include 10 percent owner David Bonderman , CHIEF MEDICAL OFFICER Donald C. Manning , and 10 percent owner Domain Partners Viii, L.p. .

Adynxx Inc (ADYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Adynxx Inc (ADYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Adynxx Inc (ADYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Adynxx Inc (ADYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adynxx Inc Insider Transactions

No Available Data

What does Onconetix Inc do?

Who are the key executives at Onconetix Inc?

James Sapirstein is the director of Onconetix Inc. Other key executives at Onconetix Inc include director & Chief Executive Officer Neil J Campbell , Chief Financial Officer Bruce Harmon , and 10 percent owner Cincinnati Cornerstone Investors Bwv I, Llc .

Onconetix Inc (ONCO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Onconetix Inc (ONCO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Onconetix Inc (ONCO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Onconetix Inc (ONCO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Onconetix Inc Insider Transactions

No Available Data

What does Clarus Therapeutics Holdings Inc do?

Who are the key executives at Clarus Therapeutics Holdings Inc?

James Sapirstein is the director of Clarus Therapeutics Holdings Inc. Other key executives at Clarus Therapeutics Holdings Inc include 10 percent owner Thomas Mcnerney & Partners Lp , director & Chief Executive Officer Robert E. Dudley , and Chief Commercial Officer Frank Jaeger .

Clarus Therapeutics Holdings Inc (CRXTQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Clarus Therapeutics Holdings Inc (CRXTQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Clarus Therapeutics Holdings Inc (CRXTQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Clarus Therapeutics Holdings Inc (CRXTQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Clarus Therapeutics Holdings Inc Insider Transactions

No Available Data

What does ZyVersa Therapeutics Inc do?

Who are the key executives at ZyVersa Therapeutics Inc?

James Sapirstein is the director of ZyVersa Therapeutics Inc. Other key executives at ZyVersa Therapeutics Inc include Chief Medical Officer Pablo A. Guzman , director & Chief Executive Officer Stephen C. Glover , and Chief Scientific Officer Labella Nicholas A. Jr. .

ZyVersa Therapeutics Inc (ZVSA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ZyVersa Therapeutics Inc (ZVSA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ZyVersa Therapeutics Inc (ZVSA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ZyVersa Therapeutics Inc (ZVSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

ZyVersa Therapeutics Inc Insider Transactions

No Available Data

What does Blue Water Acquisition Corp do?

Who are the key executives at Blue Water Acquisition Corp?

James Sapirstein is the director of Blue Water Acquisition Corp. Other key executives at Blue Water Acquisition Corp include director & Chief Executive Officer Robert E. Dudley , Chief Commercial Officer Frank Jaeger , and Chief Financial Officer Richard D Peterson .

Blue Water Acquisition Corp (BLUWU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Blue Water Acquisition Corp (BLUWU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Blue Water Acquisition Corp (BLUWU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Blue Water Acquisition Corp (BLUWU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Blue Water Acquisition Corp Insider Transactions

No Available Data

James Sapirstein Mailing Address

Above is the net worth, insider trading, and ownership report for James Sapirstein. You might contact James Sapirstein via mailing address: 1517 San Jacinto, Houston Tx 77002.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.